Johan Kördel – Sound Bioventures

All Events Fund articles Fund PR News Portfolio articles Portfolio PR

Artax Biopharma Expands Company’s Scientific Advisory Board and Welcomes James G. Krueger, M.D., Ph.D., and Ajay Nirula, M.D., Ph.D., Both Experts in T-Cell-Mediated Diseases

Cambridge, MA, November 15, 2022 Artax Biopharma, Inc., a clinical stage biotechnology company focused on transforming the treatment of T-cell-mediated diseases, today announces the Company is strengthening its Scientific Advisory Board (SAB) with the appointments of James G. Krueger, M.D., Ph.D., and Ajay Nirula, M.D., Ph.D. Artax Biopharma has an ...

Novo Holdings and Sound Bioventures launch Breye Therapeutics to develop novel oral therapies for ophthalmologic diseases

Breye Therapeutics ApS (Breye), a clinical-stage biopharmaceutical company developing novel oral therapies for retinal vascular diseases within ophthalmology, today announces it has emerged from stealth after closing a seed financing of EUR 4 million led by Novo Holdings and Sound Bioventures.

Johan Kördel is interviewed about Sound Bioventures and its Investment Strategy by BioStock

To be able to contribute to the development of new drugs is very exciting! I am passionate about helping people to a better life – says Johan Kördel Sound Bioventures strategy is to invest in private clinical stage therapeutics companies. In the interview Johan expands on the opportunity to create private spin-outs from public companies, [&he ...

Johan Kördel appears on DI TV stating that “the time to invest in Biotech is now”!

Sound Bioventures is a venture capital fund that invests in private clinical stage therapeutics companies. The managing partner Johan Kördel was invited to the Swedish financial media channel Dagens Industri (DI) to talk about the great opportunity to invest in Biotech right now: “The innovation rate keeps accelerating research and there are ...

Artax Biopharma Closes Financing to Advance Clinical Stage First-in-Class Oral Immunomodulator to Treat T Cell-Mediated Diseases

Close of $26 Million Funds Immunomodulation Candidate AX-158 Development Adds New Investors Eli Lilly and Company and Sound Bioventures Cambridge, MA, May 11, 2022 – Artax Biopharma, Inc., a clinical stage biotechnology company focused on transforming the treatment of T Cell-mediated pathologies, today announces the close of a $26 million fin ...

Thomas Tan joins Sound Bioventures

Today it was announced that Thomas Tan has joined the Sound Bioventures team as a Principal. Thomas will identify new investment opportunities, conduct scientific and commercial due diligence, and participate in board work. Prior to joining Sound Bioventures, Thomas was a senior principal at Lundbeckfonden Ventures, were he identified and managed i ...

Ester Sklarsky joins Sound Bioventures

Today we welcome Ester Sklarsky to the Sound Bioventures investment team as an Associate. Ester will manage our dealflow, identify new investment opportunities and conduct scientific and commercial due diligence. Ester joins us from Industrifonden where she made life science venture capital investments as an analyst as well as an associate. Ester a ...

Broad Media Coverage of the launch of Sound Bioventures Fund I

The launch of Sound Bioventures Fund I resulted in broad coverage of the international life science trade media and Scandinavian financial press. Our strategy to invest in clinical, or near clinical, private companies in niche/rare indications were well presented. As Bibhash put it in Biocentury “We’ll go to the best company in the spac ...

Sound Bioventures raises € 110 million for new biotherapeutics venture fund

January 4th, 2022, Malmö, Sweden and Copenhagen, Denmark: Sound Bioventures, a Scandinavia-based lifesciences venture capital firm, announced the first close of its first fund at €110 million. The fund has a geographic footprint on both sides of the Atlantic and will invest in European and US-based private biotech companies supporting the cli ...